Inhibition of phosphodiesterase 10A (PDE10A) promotes cyclic nucleotide signaling, increases striatal activation, and decreases behavioral activity. Enhanced cyclic nucleotide signaling is a well established route to producing changes in gene expression. We hypothesized that chronic suppression of PDE10A activity would have significant effects on gene expression in the striatum. A comparison of the expression profile of PDE10A knockout (KO) mice and wild-type mice after chronic PDE10A inhibition revealed altered expression of 19 overlapping genes with few significant changes outside the striatum or after administration of a PDE10A inhibitor to KO animals. Chronic inhibition of PDE10A produced up-regulation of mRNAs encoding genes that included prodynorphin, synaptotagmin10, phosphodiesterase 1C, glutamate decarboxylase 1, and diacylglycerol Oacyltransferase and a down-regulation of mRNAs encoding choline acetyltransferase and Kv1.6, suggesting long-term suppression of the PDE10A enzyme is consistent with altered striatal excitability and potential utility as a antipsychotic therapy. In addition, upregulation of mRNAs encoding histone 3 (H3) and down-regulation of histone deacetylase 4, follistatin, and claspin mRNAs suggests activation of molecular cascades capable of neuroprotection. We used lentiviral delivery of cAMP response element (CRE)-luciferase reporter constructs into the striatum and live animal imaging of 2-{4-[-pyridin-4-yl-1-(2,2,2-trifluoro-ethyl)-1H-pyrazol-3-yl]-phenoxymethyl}-quinoline succinic acid (TP-10)-induced luciferase activity to further demonstrate PDE10 inhibition results in CRE-mediated transcription. Consistent with potential neuroprotective cascades, we also demonstrate phosphorylation of mitogen-and stress-activated kinase 1 and H3 in vivo after TP-10 treatment. The observed changes in signaling and gene expression are predicted to provide neuroprotective effects in models of Huntington's disease.
Introduction
Phosphodiesterase 10A (PDE10A) is one of the 11 families of phosphodiesterases that serve to limit cyclic nucleotide signaling via enzymatic hydrolysis of these widely used second messengers. PDE enzymes are precisely localized within specific subcellular compartments to regulate discrete pools of cyclic nucleotides subserving functionally distinct signaling events (Baillie et al., 2005) . PDE10A is a dual-substrate PDE expressed at high levels within medium spiny neurons (MSNs) of both the indirect and direct output pathways of the striatum (Seeger et al., 2003; Coskran et al., 2006; Xie et al., 2006) , where it is associated primarily with membranes (Kotera et al., 2004; Xie et al., 2006) . Outside of the striatum, PDE10A seems to be associated with the perinuclear region of neurons throughout the brain (Seeger et al., 2003; Coskran et al., 2006) . In vivo pharmacological inhibition of PDE10A has been shown to produce a restricted accumulation of cGMP and cAMP within the striatum and to trigger transient increases in the phosphorylation of CREB . Other studies have shown enhanced phosphorylation of extracellular signal-regulated kinase (ERK), protein kinase A (PKA)-activated epitopes of dopamine-and cAMPregulated phosphoprotein-32, and GluR1 subunits after PDE10A inhibition (Siuciak et al., 2006a; Nishi et al., 2008; Grauer et al., 2009) .
Behavioral responses to acute inhibition with PDE10A inhibitors are consistent with striatal activation and include decreases in spontaneous and amphetamine-stimulated locomotor activity as well as disruption of conditioned avoidance responding (Siuciak et al., 2006a; Schmidt et al., 2008) . The behavioral consequences of PDE10A inhibition combined with the associated biochemical indicators of striatal activation suggest that PDE10A inhibition can enhance the signaling of medium spiny neurons to alter functional responses of the basal ganglia. Chronic suppression of PDE10A activity therefore might be expected to drive significant changes in striatal gene expression. In the current study, we used expression profiling after chronic suppression of PDE10A activity via an inhibitor or gene knockout to identify significant and overlapping changes in striatal gene expression. The observed changes in gene expression are indicative of striatal activation and a putative neuroprotective signaling cascade. We also generated lentiviral constructs to deliver a cAMP response element (CRE)-luciferase reporter into mouse striatum and used live animal imaging of light generated by the luciferase reporter to confirm the role of CRE-mediated transcription in response to PDE10A inhibition. Furthermore, acute pharmacological inhibition of PDE10A activity produced changes in the phosphorylation state of multiple signaling kinases in the ERK pathway including ERK, MSK1, and the MSK1 substrate histone 3 (H3). This cascade has been suggested to provide neuroprotection in preclinical models of Huntington's disease (HD) (Roze et al., 2008) .
Materials and Methods
Compounds. 2-{4-[-Pyridin-4-yl-1-(2,2,2-trifluoro-ethyl)-1H-pyrazol-3-yl]-phenoxymethyl}-quinoline succinic acid (TP-10) was synthesized at Pfizer Global Research and Development Laboratories in Groton, CT.
Chronic Dosing of WT and KO Animals. PDE10A knockout animals backcrossed on the C57BL6 background have been described previously (Siuciak et al., 2006b ). WT and PDE10A KO littermate mice (n ϭ 6 per group) were dosed daily for 18 days with TP-10 by oral gavage (25 mg/kg of 2.5 mg/ml solution; dose volume of 10 ml/kg) or methylcellulose vehicle (10 ml/kg body weight). Mice were housed singly and provided routine ad libitum feeding. Animals were sacrificed 1 day after the final dose of drug by CO 2 euthanasia. Brains were removed, followed by dissection of striatum, hippocampus, and frontal cortex, and snap-frozen. All animal treatment protocols were approved by Pfizer's Institutional Care and Use Committee and were compliant with Animal Welfare Act regulations.
Affymetrix Chip Profiling and Data Analysis. RNA isolation and hybridizations to mouse 430 2.0 whole genome Affymetrix (Santa Clara, CA) chips were performed by Gene Logic (Gaithersburg, MD). CEL file data were normalized by using robust multiarray analysis and subjected to pairwise comparison followed by Benjamini and Hochberg (1995) false discovery rate (FDR) correction. Probe sets with the designation "x" were removed from the dataset for potential lack of specificity. Probe translation and pathway analysis was performed using Ingenuity Pathway Analysis (IPA) software (Ingenuity Systems, Redwood City, CA). Probes that could not be translated to genes within IPA were identified by using NetAffx (Affymetrix).
RT-PCR Confirmation of Changes in Gene Expression. Total RNA was isolated from the striatum of PDE10A KO and PDE10A WT male mice (n ϭ 8 per group) by using the RNeasy Lipid Tissue Mini Kit (QIAGEN, Valencia, CA) and cDNA was made with High Capacity RNA-to-cDNA Master Mix (Applied Biosystems, Foster City, CA) using 1 g of total RNA. Quantitative RT-PCR was performed with TaqMan assays from Applied Biosystems using the primer sets detailed in Table 3 . All quantitative RT-PCR assays were performed by using TaqMan Gene Expression Master Mix (Applied Biosystems) and the following cycling conditions: 50°C hold for 2 min, 95°C hold for 10 min, and 40 cycles of 3 s at 95°C, 30 s at 60°C. Ribophorin (Rpn1) was used as the endogenous control gene, and relative quantities for gene expression were calculated by using RQ Manager software (Applied Biosystems).
Phosphoprotein Profiling. CD-1 mice dosed with vehicle, haloperidol (0.32 mg/kg), or TP-10 (3.2 mg/kg) subcutaneously in vehicle consisting of 30% ␤-cyclodextrin for the indicated times were sacrificed by 3-s focused microwave irradiation to optimally preserve the phosphorylation state of selected epitopes. Dissected striatum were placed on dry ice and stored at Ϫ70°C. Homogenates were prepared on a wt/vol basis (100 g/l) in 25 mM Tris-HCL, pH 7.4, 150 mM NaCl, 0.1% NP-40, and one complete protease inhibitor tablet (Roche Diagnostics, Indianapolis, IN). Samples homogenized on Mixer-Mill 300 (Retsch, Haan, Germany) at 25 shakes/s for 4 min were placed on wet ice with 30 l of homogenate mixed with 50 l of 4ϫ LDS sample buffer (Invitrogen, Carlsbad, CA) including 1 mM dithiothreitol and 90 l of water and warmed to 70°C for 10 min. Samples (10 l) were loaded onto EPAGE gels (Invitrogen) with seeBlueplus2 makers and transferred to nitrocellulose by using the I-blot system (Invitrogen). Membranes were blocked with Rockland (Gilbertsville, PA) Near Infrared blocking solution for 1 h, and primary antibodies were added overnight at 4°C in 50/50 Rockland Block/PBS with 0.01% Tween 20. Blots were washed in PBS/0.01% Tween 20. Incubation in secondary antibodies, goat anti-rabbit Alexa-680, and/or goat antimouse Alexa 800 (1:10K) was done before washing with PBS/0.01% Tween20 and imaging on the Odyssey System (LI-COR Biosciences, Lincoln, NE). Changes in phosphoproteins were normalized to total ERK (Cell Signaling Technology, Danvers, MA) at 1:5000. Background was removed by using the median of three pixels from above and below the band of interest. Primary phospho-specific antibodies were from the following sources and used at the indicated dilutions: ERK1/2 pTpY185/ 187 (BioSource International, Camarillo, CA) at 1:5000, pCREB ser133 (Upstate Biotechnology, Charlottesville, VA) at 1:2000, MSK pSer376 (Cell Signaling Technology) at 1:5000, and Histone pH3Ser10 (Cell Signaling) at 1:1000.
Construction of CRE-Luciferase Reporter Lentivirus. A synthetic DNA (Integrated DNA Technologies, Inc., Coralville, IA) containing six cAMP response elements (TGACGTCA) separated by seven-base pair spacers, followed by a 13-base pair minimal promoter sequence and a chimeric intron (pRL-SV40; Promega, Madison, WI) was cloned into the Xho/EcoRV sites of pGL4.10 (Promega) upstream of the luciferase gene. Subsequently, the Xba to EcoRI sites were removed and subcloned into a pLL3.7 lentiviral vector, which had been modified by using Xba and EcoRI to remove the polymerase III U6 promoter sequence. The final construct contained six copies of the cAMP response element, followed by the Elb minimal promoter and the Luciferase 2 open reading frame. High-titer lentivirus (10 9 IU/ml) for injection was produced in 293FT cells (Invitrogen). 293FT cells were transfected by using Lipofectamine 2000 per the manufacturer's instructions (QIAGEN) overnight in two T175 flasks at 70% confluence with a 3:1 ratio of Virapower Packaging Plasmids (Invitrogen) and pLL3.7 containing 6ϫCre-Luc2. Supernatants containing viral particles were collected after 14 h and concentrated over a 100-kDa frit (Millipore Corporation, Billerica, MA). Supernatants were then ultracentrifuged for 3 h, 25 rpm, at 4°C. All supernatant was then removed from the viral pellet, and 200 l of PBS was added. The pellet was resuspended by gentle rocking overnight at 4°C. Viral particles were aliquoted in 10-l volumes and stored at Ϫ80°C until used. Functional viral titers were determined by flow cytometry using a BD FACSCalibur (BD Biosciences, San Jose, CA).
Stereotaxic Injection. Fifteen male CD-1 mice (60 -90 days old) were ordered from Charles River Breeding Laboratories (Portage, MI) and acclimated in-house for 1 week before the start of the experiment. Mice were housed in 12:12 light/dark cycle and fed standard chow available ad libitum. On the day of the stereotaxic surgery each mouse was anesthetized with isoflurane (2% in oxygen). The top of the head was shaved, and the mouse was placed in a stereotaxic frame. The eyes were coated with lubricant to prevent drying out, and the shaved portion of the head and surrounding area was disinfected. Using a 15 blade, a midline skin incision was made, and a sterile swab was used to dry the surface of the scull. Measurements were made from bregma, and a small burr hole was drilled at the site of the injection. The coordinates used for the striatal injections were as follows: left striatum ϭ anterior/posterior ϩ 0.5, lateral ϩ 2.0, dorsal/ventral (D/V) (Ϫ) 3.0 to 2.0 mm. Each mouse received 2 l of high-titer lentivirus into the left striatum. The virus was delivered by using a 10-l Hamilton (Reno, NV) syringe with a 30-g blunt tip needle. The syringe was attached to a syringe pump to enable precise flow rate and volume. For the injection, the needle was slowly inserted to the first D/V coordinate and left in place for 4 min to allow the tissue to settle. The virus was injected at a rate of 0.25 l/min. After 1 l was injected (4 min) the needle was slowly raised to the second D/V coordinate for the second 1-l injection (remaining 4 min). When the injection was complete the needle was left in place for an additional 4 min to allow for diffusion of the virus into the surrounding tissue before being slowly withdrawn. The animals were sutured with 6.0 absorbable Vicryl polysorb suture and administered a single 5 mg/kg s.c. injection of Rimadyl (carprofen) and 500 l of saline subcutaneously A topical antibiotic was used on the incision site, and the animals were allowed to recover in a warm cage before returning to the holding room.
Imaging of CRE-Luciferase Reporter. Mice were imaged by using an IVIS 200 Bioluminescent Imaging System (Caliper Life Sciences, Hopkinton, MA). Each mouse was injected intraperitoneally with 150 mg/kg D-luciferin Kϩ salt (Caliper Life Sciences) substrate 10 min before imaging. The mice were then anesthetized with 2.5 to 3% isoflurane in oxygen, placed in the prone position on the IVIS platform, and imaged for 1 min. Baseline images were obtained immediately before injection of TP-10 compound (3.2 mg/kg s.c. in 10% ␤-cyclodextrin vehicle). Sixteen hours after TP-10 administration, the mice were imaged again. Images obtained from the IVIS 200 are an overlay of the bioluminescent signal as a pseudocolor image on a black and white photograph. Data are presented as total photon flux (photons/s) from a 1.5-cm 2 circular region of interest. Histology. Ten weeks after lentiviral injection, three mice were selected for histological analysis to assess the efficiency of lentiviral transduction in the striatum. The mice were deeply anesthetized with sodium pentobarbital and transcardially perfused with ice-cold saline, followed by ice-cold 4% paraformaldehyde solution in phosphate buffer. The brains were removed and postfixed overnight in 4% paraformaldehyde at 4°C before transferring to a 20% sucrose solution in phosphate buffer. Brains were sectioned and stained with rabbit polyclonal anti-green fluorescent protein (A11122; Invitrogen) at FD Neurotech (Ellicott City, MD).
Results
Chronic Genetic and Pharmacological Suppression of PDE10A Enzyme Activity Produces Significant Changes in Striatal Gene Expression. Vehicle or TP-10, a selective PDE10A inhibitor (IC 50 ϭ 0.3 nM; Schmidt et al., 2008) , was administered once daily for 18 days to both WT and PDE10A KO mice. Oral administration of TP-10 at 25 mg/kg resulted in a free plasma concentration of 7 nM or Ͼ10-fold above the PDE10A IC 50 1 h after drug administration (data not shown). Because TP-10 is brain permeable, this dose should completely inhibit the enzyme and provide a comparator for changes in gene expression between WT and KO animals. Given the high degree of selectivity (Ͼ1000 fold) of TP-10 over all other PDE enzymes, no off-target PDE activity is expected to contribute to the changes in gene expression identified. This was confirmed by examination of the effect of TP-10 on differential gene expression in PDE10A KO mice, which produced no statistically significant change in gene expression for any genes in either striatum or hippocampus after correction for multiple comparisons using a Benjamini and Hochberg FDR of p Ͻ 0.05.
After chronic dosing with vehicle or TP-10, RNA was isolated from striatum and hippocampus and subjected to microarray hybridization. After robust multiarray analysis normalization of hybridization intensities, pairwise comparisons were made between vehicle and TP-10 treatment for WT and PDE10A KO animals and between the WT and KO animals followed by application of the Benjamini and Hochberg correction for multiple comparisons. Changes in striatal gene expression that exhibited statistically significant differences between vehicle and TP-10 in WT animals (FDR p Ͻ 0.05) are displayed in Table 1 , rank-ordered by observed fold change in expression. Among the mRNAs significantly affected by TP-10 treatment were several transcripts encoding genes involved in neurotransmitter synthesis or catabolism, including a 1.38-fold down-regulation of the mRNA for the acetylcholine synthetic enzyme ChAT. In addition, a 1.2-fold upregulation of mRNA for the GABA synthetic enzyme GAD67 and 4-aminobutyrate aminotransferase, a GABA catabolic enzyme, was observed after chronic TP-10 treatment. Likewise, the dynorphin precursor prodynorphin was significantly up-regulated 1.76-fold after chronic TP-10 treatment. ChAT and prodynorphin were similarly affected in the WT versus KO comparison. The arginase type II enzyme, responsible for limiting the availability of arginine required for production of the neurotransmitter NO, was up-regulated by both TP-10 treatment and KO versus WT comparisons, but reached statistical significance only in the TP-10-treated WT animals. In addition to neurotransmitter regulation, many genes involved in neurotransmission and neuronal excitability were altered by chronic exposure to TP-10, including synaptotagmin X (increased 1.6-fold), the voltage-gated potassium channel protein Kv1.6 (decreased 1.64-fold), the dihydropyridine-sensitive L-type calcium channel ␤3 subunit (decreased 1.5-fold), and the synaptic rhoGEF kinase kalirin (decreased 1.6-fold). The specificity of the TP-10-induced changes was highlighted by the lack of any significant changes in transcript levels identified in the KO after TP-10 treatment, including any significant changes among genes identified as significant after TP-10 treatment in the WT mice (p values are presented in Table 1 ). Very few significant changes were observed between WT and KO comparisons of hippocampus (Rab11b, Lix1, Lnpep, and Psmc2; FDR Ͻ0.05), and of these only two were larger than a 1.3-fold change (Lix1 and Lnpep). Only two probe sets were altered in hippocampus after TP-10 treatment, and they did not map to any known genes, indicating that the chronic changes in gene TABLE 1 Genes encoded by transcripts that were significantly altered in mouse striatum after chronic pharmacological inhibition of PDE10A activity, after correction for multiple comparisons A comparison between PDE10A KO and WT striatum for each pharmacologically regulated gene is shown with the associated FDR corrected p value and fold change. Significant changes across treatments are underlined. No significant pharmacologically induced differences were observed after TP-10 treatment in the PDE10A knockout animals, consistent with the specificity of these effects via PDE10A inhibition. Genes represented in bold were reported to be cAMP-responsive genes by Zhang et al. (2005) .
Gene Symbol
Gene Name 
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at ASPET Journals on November 13, 2017 jpet.aspetjournals.org expression were confined largely to the striatum, where PDE10A expression is most highly concentrated (Seeger et al., 2003; Coskran et al., 2006) . A complete list of striatal genes that displayed significant differential expression in a comparison of WT versus KO gene expression (FDR p Ͻ 0.05) is in Table 2 . A set of 21 probe sets representing 19 potential genes was significantly altered in both TP-10-treated versus vehicle as well as in the PDE 10 KO versus WT comparisons and is underlined in Table 1 . We were able to identify 18 overlapping genes with Taqman assays for quantitative RT-PCR comparisons between untreated WT and KO striatum by using a separate cohort of similarly aged animals to provide independent confirmation of affected genes (probe set 1460043at was significant across both comparisons and mapped to an the unidentified cDNA mM.405423; it was not evaluated because Taqman assays were not available). Seven additional genes exhibited a significant change in the Affymetrix chip analysis of vehicle versus TP-10 comparison and were selected for RT-PCR confirmation in a replicate cohort of PDE10A WT and KO animals. Transcripts encoding 15 of the 18 expected overlapping genes, an additional three genes with less stringent FDR corrected p values for the WT versus KO comparison (p ϭ 0.1 and 0.25), showed experimentally determined changes in gene expression via RT-PCR and are shown in Table 3 . This result suggests that stringent statistical criteria using a FDR correction of p Ͻ 0.05 may slightly underestimate the actual number of genes in the overlapping sets; however, we failed to replicate the significant effect of chronic PDE10A suppression on ChAT mRNA by RT-PCR, despite observed changes in both WT versus KO and TP-10 versus vehicle comparisons, demonstrating that there is not perfect correspondence between methods. The relative magnitude and direction of changes in gene expression observed by RT-PCR matched observations from Affymetrix chip data.
To facilitate pathway-level analysis of changes in gene expression produced by chronic PDE10A suppression, two different approaches were taken to analyze the data. First, the significantly affected genes that survived FDR correction were analyzed with IPA software (version 8.0) to identify top-scoring canonical pathways. The eukaryotic initiation factor-4 pathway was identified as the sole overlapping pathway via identification of two pathway genes (EIF2C4, PPP2R5B) present in both TP-10-induced genes and KO- induced gene sets. This was in contrast to observations that 21 of the 95 probes sets altered by TP-10 were also significantly altered in the KO versus WT comparison. The latter comparison yielded 68 probe sets significantly altered out of 45,101 monitored on the microarray. Given the size of these datasets relative to the number of total probe sets measured, only 0.14 probe sets would be expected to overlap by random chance. The identification of 21 overlapping significant probe sets is highly significant using a Poisson approximation of binomial probability (p ϭ 2.814 ϫ 10 Ϫ38 ). In addition, a strong correlation (r 2 ϭ 0.9) was observed between the direction and fold change in the 19 genes that were significantly altered in both the WT versus KO and the TP-10 versus vehicle comparisons (Fig. 1) .
Identification of a single overlapping pathway between these data sets suggests that the FDR correction may result in too small a data set for pathway analysis. To explore this possibility, we repeated pathway analysis using larger gene sets chosen according to their uncorrected p values. We selected genes with nominal p value Ͻ 0.01 and a minimum fold change Ͼ 1.2 for analysis in IPA. Using these criteria we found 364 probe sets after chronic PDE10A inhibition and 289 probe sets altered in PDE10A KO (Supplemental Table  1 ). Analysis of these probe sets using IPA software highlighted statistically significant differences in four common canonical pathways (highlighted in bold in Table 4 ). These pathways included the polo-like kinases, which includes checkpoint kinases, the p38/mitogen-activated protein kinase (ERK) pathway, the PKA pathway, and ␤-adrenergic signaling. In addition, a significant enrichment was observed in a cAMP-responsive CREB gene list described previously by Zhang et al. (2005) , which is identified in bold in Tables 1  and 2 . We also identified genes altered after TP-10 treatment of PDE10A KO striatum for comparison with the same criteria used for IPA pathway analysis. Although no genes reached statistical significance after correction for multiple comparisons, 34 genes were identified with a nominal p value of less than 0.01 and a more than 1.2-fold change (Supplementary Table 2 ). However, none of these genes overlapped with those identified after drug treatment in the WT animals.
Consistent with the effects on two of these pathways, acute PDE10A inhibition has been reported previously to produce changes in cAMP and the phosphorylation state of PKA pathway targets including pCREB, GluR1 Ser845, and dopamineand cAMP-regulated phosphoprotein-32 Thr34 (Nishi et al., 2008; Grauer et al., 2009) . Likewise, the phosphorylation of ERK has been reported previously in response to PDE10A inhibition, suggesting the identified overlapping pathways accurately reflect the effects of PDE10A disruption. A common theme among PKA-and ERK-affected pathways is that they have been proposed previously as therapeutic strategies for treating Huntington's disease (Steffan et al., 2000; Giampà et al., 2006; Roze et al., 2008) .
Acute Administration of TP-10 Drives CRE-Mediated Transcription within the Striatum In Vivo. To further demonstrate the functional effects of CREB phosphorylation 
TABLE 4
Canonical pathways identified by ingenuity pathway analysis of statistically significant genes (P Ͻ 0.01, without FDR correction) and a more than 1.2-fold difference between TP-10 and vehicle-treated mouse striatum or between PDE10 KO and WT mouse striatum Genes used for pathway analysis are listed in Supplementary Table 1. Pathways identified in bold text were determined to be significantly affected in both comparisons. 
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at ASPET Journals on November 13, 2017 jpet.aspetjournals.org on transcriptional activation, we created a reporter vector with 6ϫ-CRE upstream of a luciferase reporter gene cloned into a lentiviral (pLL3.7) vector. High-titer virus was prepared and stereotaxically administered to the striatum of adult mice. Animals were allowed to recover for 1 week before the administration of TP-10 (3.2 mpk s.c.) and subsequent imaging. A separate cohort of animals that received stereotaxic injection of the CRE-luciferase lentiviral reporter into the striatum showed that the peak transcriptional response in response to PDE10A inhibition was detected via in vivo imaging of luciferase activity at 16 h after drug treatment (data not shown). This is consistent with a need to translate and accumulate sufficient luciferase enzyme before significant detection of a bioluminescent enzyme-derived signal over skulls of treated animals. All studies were subsequently carried out approximately 16 h after drug treatment, when animals were administered luciferase substrate (luciferin) and briefly anesthetized for imaging on an IVIS bioimager. Baseline imaging of animals showed no significant luciferase bioluminescence in the brains of injected animals. TP-10-injected animals exhibited robust bioluminescence over brain regions approximating the striatum, confirming a robust transcriptional activation of the striatally injected reporter construct ( Fig. 2A) . Repeated injection and imaging of these mice demonstrated the response of the reporter construct was stable over several weeks (Fig. 2B ). Animals were sacrificed 10 weeks after stereotaxic injection, and histochemical verification of the striatal location for the reporter expression of GFP was confirmed ( Fig. 2A) .
Acute Inhibition of PDE10A Increased Phosphorylation of Striatal ERK Substrates. To further probe the ERK pathway, we evaluated the phosphorylation state of several potential ERK pathway components after PDE10A inhibition, including ERK, MSK, and H3. Mice were administered 3.2 mpk of TP-10 subcutaneously, a dose previously shown to produce elevations of striatal cAMP and cGMP as well as activity in established models of antipsychotic efficacy . Western blot analysis of samples probed with antibodies to phospho-epitopes of ERK (ERK1/2 pTpY185/187) and MSK1 (Ser376) found both kinases phosphorylated rapidly and transiently after PDE10A inhibition, returning to baseline levels by 3 h after drug administration (Fig. 3) . MSK has been reported to phosphorylate both CREB and H3, both of which can alter gene transcription (Deak et al., 1998; Arthur, 2008) . Consistent with this relationship, we observed an enhanced phosphorylation of Ser10 on H3, a substrate for MSK1 (Fig. 3) . It is worth noting that we also observed significant up-regulation of H3 mRNA in Affymetrix chip studies after chronic PDE10A inhibition (1.4-fold, p ϭ 0.01 after FDR correction).
MSK1 is reported to be phosphorylated within striatonigral and striatopallidal MSNs in response to cocaine and haloperidol, respectively (Heffron and Mandell, 2005; Bertran-Gonzalez et al., 2008) . In our hands, the haloperidolinduced phosphorylation of ERK and MSK1 was significantly smaller than that observed after inhibition of PDE10A, consistent with the mechanistic distinction that the D2 antagonist activates only a subset of MSNs versus the simultaneous Fig. 2 . Transduction of neurons in striatum with lentiviral CRE-luciferase reporter yields activation of CREBmediated transcription of luciferase reporter in vivo in response to PDE10 inhibition. Stereotaxic delivery of lentiviral CRE-luciferase reporter into striatum was completed 1 week before the first TP-10 treatment. A, mice were administered luciferin substrate (150 mpk i.p.) 10 min before collection of baseline images using the IVIS platform. Subsequently, TP-10 or vehicle (3.2 mpk s.c.) was administered to 15 animals per treatment group, and repeated imaging of animals was conducted 16 h after drug treatment. Confirmation of the location of stereotaxic delivery was evaluated 10 weeks after lentiviral transduction by immunohistochemical verification of GFP signal driven by lentiviral construct. Animals were administered equivalent doses of TP-10 and imaged weekly. B, quantitation of luciferase signals collected from all animals 1 week after lentiviral transduction (top) and 6 weeks after lentiviral transduction (bottom) is shown.
activation of striatonigral and striatopallidal neurons by PDE10A inhibition (Fig. 4) . Consistent with this, haloperidol did not produce detectable phosphorylation of MSK1 by Western blot analysis. The dose of haloperidol used in this experiment (0.32 mg/kg s.c.) was eight times higher than that needed to produce an ED 50 response in the conditioned avoidance responding assay . This assay is thought to be predictive of antipsychotic activity. By comparison, the 3.2 mg/kg dose of TP-10 used in this experiment is only three times the dose required to produce a ED 50 response in the conditioned avoidance response assay . Thus, the smaller changes in phosphorylation produced by haloperidol compared with TP-10 are not caused by the subthreshold activity of the drug. The enhanced MSK1 phosphorylation during PDE10A inhibition treatment likely occurs in all MSNs; however, the higher expression of MSK1 in D1-containing neurons (Bertran-Gonzalez et al., 2009 ) may contribute to the larger signal observed after TP-10 administration. The MSK1 substrate H3 showed an identical pattern of phosphorylation.
Discussion
The current study used microarray profiling to characterize and contrast the effects of genetic and pharmacological disruption of PDE10A. Changes in gene expression produced by both approaches implicate PDE10A in the regulation of signaling cascades that impinge on PKA, ERK, and checkpoint kinase-mediated pathways. The lack of any significant changes in gene expression produced by the PDE10A inhibitor TP-10 in PDE10A KO animal speaks to the high degree of specificity of the gene expression signature produced by TP-10 in WT animals. Likewise, the restriction of changes in gene expression identified within this study largely to the striatum, despite evaluation of microarray data collected from hippocampus, suggests a lack of circuit-level regulation of gene expression in other structures. These observations illustrate the utility of using negative microarray data to demonstrate specificity of pathway manipulations and differentiate PDE10A inhibitors from other antipsychotic approaches that have been reported previously to alter gene expression in frontal cortex and striatal regions in rodents (MacDonald et al., 2005) .
Analysis of changes in gene expression provides insight into the striatal neurotransmitter systems regulated by prolonged PDE10A inhibition with TP-10. The down-regulation of mRNA encoding cholinergic synthetic enzyme ChAT and up-regulation of mRNA for the L-arginine catabolic enzyme arginase II, in both PDE10A KO mice and after PDE10A inhibition, would be expected to decrease availability of acetylcholine and NO, both used as neurotransmitters by striatal interneurons. PDE10A protein is absent from striatal cholinergic interneurons (Coskran et al., 2006) , suggesting min, peaked at 30 min, and began to drop off by 60 min. The MSK1 phosphorylation state was returned to baseline by 3 h after drug treatment. A similar profile was observed for the phosphorylation profile of the MSK1 substrate H3, which was phosphorylated at Ser10 with a similar time course.
C-E, quantitative analysis of the phosphorylated (p)ERK (C), pMSK (D), and pH3 (E) band intensity after normalization to total ERK band or total NR1 protein (imaged in second channel on same blot) using the LI-COR Odyssey platform.
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at ASPET Journals on November 13, 2017 jpet.aspetjournals.org CREM, the cAMP responsive element modulator protein that contributes negative feedback control of CREB signaling (De Cesare and Sassone-Corsi, 2000) . Thus, several compensatory mechanisms to counteract the enhanced ERK and CREB signaling have been invoked in the knockout animals that are not obvious after inhibitor treatment. Several lines of evidence suggest changes in transcriptional profiles produced by suppression of PDE10A activity may offer neuroprotection in HD. Transcripts for PDE10A and PDE1B are abundant in striatum, but exhibit significant down-regulation in HD brain and the R6/2 mouse model. The decrease in PDE10A mRNA is caused by decreases in transcriptional initiation of the striatally expressed PDE10A2 gene, which initiates at sites 2 and 3 in the exon 1a-specific promoter (Hu et al., 2004) , and loss of the PDE10A enzyme early in disease has been proposed as a contributing factor in progression of disease . However, the loss of striatally enriched transcripts early in disease or R6/2 model progression could be a consequence of transcriptional dysfunction caused by a direct interaction of soluble huntingtin protein with transcription factors required to direct expression of particular mRNAs or compensation for dysfunctional neuronal signaling. Studies of the regulation of the PDE10A promoter have not revealed any candidate regulatory transcription factors capable of decreasing PDE10A mRNA as observed in the R6/R2 mouse model (Hu et al., 2004) . Given that inhibition of PDE10A is a powerful inducer of CREB-mediated transcription in striatum, and the propensity of this circuit to compensate for chronic deficits in signaling cascades, it seems possible that down-regulation of PDE10A early in the disease process may be an adaptive response to compensate for loss of cAMP signaling. If so, therapeutic inhibition of the enzyme earlier in the disease (before loss of the enzyme) may stall its progression. Consistent with this, Giampà et al. (2009) have reported that chronic PDE10A inhibition with TP-10 can provide striatal neuroprotection from quinolinic acid lesions of the striatum. This group has also observed neuroprotection and improved life expectancy in the R6/2 HD model with chronic administration of the PDE10A inhibitor TP-10 (Giampà et al., 2010) . Down-regulation of key transcripts identified in the current study after chronic TP-10 treatment may contribute to this neuroprotective effect including follistatin, claspin, and histone deacetylase (HDAC) 4. Follistatin is an endogenous antagonist of activin, and its mRNA is highly enriched in MSNs from the D1-containing neurons in the direct pathway (Doyle et al., 2008) . Direct striatal administration of recombinant human activin A has been demonstrated to be neuroprotective in the quinolinic acid model of striatal neurodegeneration (Hughes et al., 1999) . In addition, PDE10A inhibition induced a large down-regulation of claspin, a checkpoint kinase (Mrc1) involved in S-phase checkpoint damage detection. Expanded CAG/CTG repeats can be detected by checkpoint machinery via changes in their secondary structure. These expansions are prone to chromosome breakage requiring DNA repair. Detection of DNA damage within neurons has been associated with the induction of apoptotic cell death. Claspin checkpoint kinase (Mrc1) inhibitors have been proposed as promising therapeutic target for degenerative trinucleotide repeat diseases including Huntington's disease . HDAC inhibitors have also been proposed as therapeutic treatment for HD. The HDAC inhibitor 4b, expected to inhibit both HDAC3 and HDAC4, provides significant neuroprotection in the R6/2 model of HD (Thomas et al., 2008) , and the genetic knockdown of HDAC4 has been reported to improve the HD phenotype in the R6/2 mouse (Bates, 2009) . The down-regulation of HDAC4 after chronic TP-10 treatment may provide an alternative path to decreasing HDAC activity.
The potential significance of robust activation of the ERK pathway by TP-10 in striatum is highlighted by studies in Huntington's disease animal models and postmortem HD brain analysis suggesting deficiencies in MSK1-induced phosphorylation of H3 or its transcription may contribute to the degeneration of striatal neurons (Roze et al., 2008) . Consistent with the activation of the ERK cascade, we found enhanced phosphorylation of the nuclear ERK substrate MSK1 at Ser376, an autophosphorylation site that suggests kinase activation (McCoy et al., 2005) . The overexpression of MSK1 has been demonstrated to provide neuroprotection in vitro models of polyglutamine expansion, suggesting that MSK1 activation, or downstream up-regulation of histonemediated modifications, may be a viable approach to the treatment of Huntington's disease (Roze et al., 2008) . This is the first study to characterize the consequences of chronic PDE10A suppression on gene expression. We have identified several novel changes in signaling within the ERK cascade that support the therapeutic potential of PDE10A inhibitors in the treatment of both psychosis and HD. Observed changes in gene expression within striatal neurotransmitter systems are consistent with previous predictions that PDE10A inhibition may be a novel approach to the treatment of schizophrenia by enhancing striatal output. The specific biochemical and transcriptional pattern of activity produced by PDE10A inhibition reported here also points to the potential application of such agents in neurodegenerative conditions such as HD. The current microarray analysis highlights the power of evaluating therapeutic targets from both genetic and pharmacological perspectives to gain a broader insight into the biological system affected and more fully evaluate the therapeutic potential of novel biological targets.
